Endoscopic balloon dilation of Crohn’s disease strictures-safety, efficacy and clinical impact

Table 3 Baseline characteristics comparison between anastomotic and non-anastomotic strictures n (%)

Characteristic	Anastomotic strictures (n = 43)	Non-anastomotic strictures (n = 37)	P value
Female/male (n)	19/24	22/15	0.173
Disease duration in years (median; min-max)	19.2 (5.7-52.1)	16.3 (3.0-45.3)	0.236
Follow-up since 1st dilation in years (median; min-max)	4.4 (1.3-6.8)	2.9 (1.2-6.5)	< 0.001
Time between 1st and 2nd dilation in days (median; min-max)	453.5 (152-1362)	368 (157-1705)	0.796
Age at index colonoscopy (mean; standard deviation)	44.9 (± 12.2)	39 (± 12.2)	0.035
Montreal classification
Age at diagnosis			0.368
A1	6 (14)	4 (12.9)
A2	29 (67.4)	25 (80.6)
A3	8 (18.6)	2 (6.5)
Disease location			0.057
L1	23 (53.5)	9 (29)
L2	1 (2.3)	4 (12.9)
L3	17 (39.5%)	14 (45.2%)
L1-4	2 (4.7%)	3 (9.7%)
L3-4	-	1 (3.2%)
Behavior
B1	1 (2.3)	4 (12.9)	0.071
B2	22 (51.2)	19 (61.3)	0.387
B3	20 (46.5)	8 (25.8)	0.07
Perianal disease	12 (27.9)	9 (29)	0.916
Smoking habits			0.635
Non-smoker	22 (52.4)	11 (44)
Ex-smoker	8 (19)	9 (36)
Current smoker	12 (28.6)	5 (20)
Medication at index colonoscopy
Thiopurines	23 (53.5)	25 (67.6)	0.200
Anti-TNFα	17 (39.5)	19 (51.4)	0.289
Obstructive symptoms	15 (35.7)	10 (27.8)	0.454
C-reactive protein	2.8 (0.3-18.4)	6.95 (0.2-35.5)	0.126
Calprotectin	103.5 (5.9-1356)	283 (166-321)	0.789
Lactoferrin	7.66 (1.05-204.4)	10.7 (7.1-22.7)	0.429
Need to repeat dilation	27 (62.8)	15 (40.5)	0.047

TNFα: Tumor necrosis factor α.